# Pacritinib With Aza for Upfront Myelodysplastic Syndrome

> **NCT07387354** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Thomas Jefferson University** · enrollment: 25 (estimated)

## Conditions studied

- Myelodysplastic Syndromes
- MDS
- Myelodysplastic Syndrome, Unclassifiable
- Hematologic Diseases
- Bone Marrow Disease
- Myeloproliferative Neoplasm

## Interventions

- **DRUG:** Pacritinib
- **DRUG:** Azacitidine
- **PROCEDURE:** Bone Marrow Biopsy and Aspirate
- **DIAGNOSTIC_TEST:** Laboratory Testing
- **DIAGNOSTIC_TEST:** Electrocardiogram
- **OTHER:** Quality of Life in Myelodysplasia Scale

## Key facts

- **NCT ID:** NCT07387354
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07387354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07387354, "Pacritinib With Aza for Upfront Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07387354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*